YU491A - 3-AMINOPIPERIDINSKI DERIVATIVES - Google Patents
3-AMINOPIPERIDINSKI DERIVATIVESInfo
- Publication number
- YU491A YU491A YU491A YU491A YU491A YU 491 A YU491 A YU 491A YU 491 A YU491 A YU 491A YU 491 A YU491 A YU 491A YU 491 A YU491 A YU 491A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- aminopiperidinski
- derivatives
- phenylpiperidine
- aminopiperidine
- divisional
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
3-Amino-2-phenylpiperidine is a valuable intermediate for the preparation of certain 3-aminopiperidine substance P antagonists. (Divisional of application no 90313680.2).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1990/000116 WO1991009844A1 (en) | 1990-01-04 | 1990-01-04 | Substance p antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
YU491A true YU491A (en) | 1994-01-20 |
YU48026B YU48026B (en) | 1996-10-09 |
Family
ID=22220614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU491A YU48026B (en) | 1990-01-04 | 1991-01-03 | 3-AMINOPIPERIDINSKI DERIVATIVES |
Country Status (27)
Country | Link |
---|---|
EP (2) | EP0436334B1 (en) |
JP (1) | JPH0757748B2 (en) |
KR (1) | KR930009441B1 (en) |
CN (2) | CN1035944C (en) |
AT (1) | ATE115127T1 (en) |
AU (1) | AU625511B2 (en) |
BR (1) | BR9100016A (en) |
CA (1) | CA2033497C (en) |
CZ (1) | CZ289485B6 (en) |
DE (1) | DE69014848T2 (en) |
DK (1) | DK0436334T3 (en) |
ES (1) | ES2064667T3 (en) |
FI (2) | FI114096B (en) |
GR (1) | GR3014940T3 (en) |
HU (5) | HU222724B1 (en) |
IE (1) | IE63770B1 (en) |
IL (3) | IL112348A (en) |
MY (1) | MY105438A (en) |
NO (1) | NO178187C (en) |
NZ (1) | NZ236581A (en) |
PL (5) | PL164244B1 (en) |
PT (1) | PT96405B (en) |
RU (1) | RU2105758C1 (en) |
UA (1) | UA41251C2 (en) |
WO (1) | WO1991009844A1 (en) |
YU (1) | YU48026B (en) |
ZA (1) | ZA9136B (en) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218364B1 (en) | 1988-06-20 | 2001-04-17 | Scott L. Harbeson | Fluorinated neurokinin A antagonists |
US5830863A (en) * | 1988-06-20 | 1998-11-03 | Merrell Pharmaceuticals Inc. | Neurokinin A antagonists |
US5332817A (en) * | 1990-01-04 | 1994-07-26 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles |
US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
ES2093099T3 (en) * | 1990-05-31 | 1996-12-16 | Pfizer | PREPARATION OF SUBSTITUTED PIPERIDINES. |
ES2063507T3 (en) * | 1990-06-01 | 1995-01-01 | Pfizer | 3-AMINO-2-ARYL-QUINUCLIDINES, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
ATE116317T1 (en) * | 1990-07-23 | 1995-01-15 | Pfizer | QUINUCLIDINE DERIVATIVES. |
RU2105001C1 (en) * | 1991-03-26 | 1998-02-20 | Пфайзер Инк. | Method of synthesis of substituted 3-aminopiperidine |
US5716965A (en) * | 1991-05-22 | 1998-02-10 | Pfizer Inc. | Substituted 3-aminoquinuclidines |
DE9290083U1 (en) * | 1991-06-20 | 1994-02-17 | Pfizer Inc., New York, N.Y. | Fluoroalkoxybenzylamino derivatives of nitrogen-containing heterocycles |
TW202432B (en) * | 1991-06-21 | 1993-03-21 | Pfizer | |
EP0600952B1 (en) * | 1991-08-20 | 1996-04-17 | MERCK SHARP & DOHME LTD. | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
EP1082959A1 (en) * | 1991-09-20 | 2001-03-14 | Glaxo Group Limited | NK1 Antagonists for the treatment of depression |
GB9201179D0 (en) * | 1992-01-21 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
FR2688219B1 (en) | 1992-03-03 | 1994-07-08 | Sanofi Elf | AMATONIUM QUATERNARY SALTS OF AMINO AROMATIC COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
AU675786B2 (en) * | 1992-04-15 | 1997-02-20 | Merck Sharp & Dohme Limited | Azacyclic compounds |
US5444074A (en) * | 1992-04-15 | 1995-08-22 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
DK0641328T3 (en) * | 1992-05-18 | 2002-05-21 | Pfizer | Bridged, azabicyclic derivatives as substance P antagonists |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
CA2099233A1 (en) * | 1992-06-29 | 1993-12-30 | Conrad P. Dorn | Morpholine and thiomorpholine tachykinin receptor antagonists |
US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
US5637699A (en) * | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
ES2124318T3 (en) * | 1992-07-28 | 1999-02-01 | Merck Sharp & Dohme | AZACICLIC COMPOUNDS. |
WO1994003445A1 (en) * | 1992-08-04 | 1994-02-17 | Pfizer Inc. | 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists |
GB9216911D0 (en) * | 1992-08-10 | 1992-09-23 | Merck Sharp & Dohme | Therapeutic agents |
US5387595A (en) * | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
US5563161A (en) * | 1992-09-10 | 1996-10-08 | Merck Sharp & Dohme Ltd. | Alcohols and ethers with aromatic substituents as tachykinin-antagonists |
GB9220286D0 (en) * | 1992-09-25 | 1992-11-11 | Merck Sharp & Dohme | Therapeutic agents |
US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
ATE194340T1 (en) * | 1992-12-10 | 2000-07-15 | Pfizer | AMINOMETHYLENE SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SUBSTANCE PANTAGONISTS |
US6369074B1 (en) * | 1992-12-10 | 2002-04-09 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists |
US5830854A (en) * | 1992-12-14 | 1998-11-03 | Merck Sharp & Dohme, Limited | Method of treating cystic fibrosis using a tachykinin receptor antagonist |
GB9300051D0 (en) * | 1993-01-04 | 1993-03-03 | Merck Sharp & Dohme | Therapeutic agents |
CA2152925A1 (en) * | 1993-02-18 | 1994-09-01 | Raymond Baker | Azacyclic compounds compositions containing them and their use as tachykinin antagonists |
US5496833A (en) * | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
DE69404306T2 (en) * | 1993-05-28 | 1997-10-30 | Pfizer | METHOD FOR THE PRODUCTION AND OPTICAL RESOLUTION OF 2-PHENYL-3-AMINOPIPERIDINE |
US5348955A (en) * | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
GB9317104D0 (en) * | 1993-08-17 | 1993-09-29 | Zeneca Ltd | Therapeutic heterocycles |
EP1209157A1 (en) * | 1993-09-17 | 2002-05-29 | Pfizer Inc. | Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds |
US6083943A (en) * | 1993-09-17 | 2000-07-04 | Pfizer Inc | Substituted azaheterocyclecarboxylic acid |
EP0719253B1 (en) * | 1993-09-17 | 2004-04-28 | Pfizer Inc. | 3-amino-5-carboxy-substituted piperidines and 3-amino-4-carboxy-substituted pyrrolidines as tachykinin antagonists |
IS4208A (en) * | 1993-09-22 | 1995-03-23 | Glaxo Group Limited | 3- (tetrazolyl-benzyl) amino-piperadidine derivatives |
CA2181376A1 (en) * | 1994-01-28 | 1995-08-03 | Malcolm Maccoss | Aralkylamino substituted azacyclic therapeutic agents |
US5610165A (en) * | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
GB9408872D0 (en) * | 1994-05-03 | 1994-06-22 | Zeneca Ltd | Heterocyclic compounds |
GB9418545D0 (en) * | 1994-09-15 | 1994-11-02 | Merck Sharp & Dohme | Therapeutic agents |
FR2725900B1 (en) * | 1994-10-21 | 1997-07-18 | Sanofi Sa | USE OF NK1 RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS WITH CARDIOREGULATORY ACTION |
EP0709375B1 (en) * | 1994-10-25 | 2005-05-18 | AstraZeneca AB | Therapeutic heterocycles |
US5998444A (en) * | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
US6008223A (en) * | 1994-10-27 | 1999-12-28 | Zeneca Limited | Therapeutic compounds |
FR2728169A1 (en) | 1994-12-19 | 1996-06-21 | Oreal | USE OF A SUBSTANCE P ANTAGONIST FOR THE TREATMENT OF PRURITUS AND EYE OR PALPEBRAL DYSESTHESIA |
FR2728165A1 (en) | 1994-12-19 | 1996-06-21 | Oreal | USE OF AN ANTAGONIST OF SUBSTANCE P FOR THE TREATMENT OF SKIN REDNESS OF NEUROGENIC ORIGIN |
FR2728166A1 (en) | 1994-12-19 | 1996-06-21 | Oreal | TOPICAL COMPOSITION CONTAINING AN ANTAGONIST OF SUBSTANCE P |
FR2729952B1 (en) * | 1995-01-30 | 1997-04-18 | Sanofi Sa | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2729954B1 (en) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2741262B1 (en) | 1995-11-20 | 1999-03-05 | Oreal | USE OF A TNF-ALPHA ANTAGONIST FOR THE TREATMENT OF CUTANEOUS REDNESS OF NEUROGENIC ORIGIN |
ES2180693T3 (en) | 1995-12-21 | 2003-02-16 | Pfizer | 3 - ((BENCIL 5-SUBSTITUTED) AMINO) -2-PHENYLPIPERIDINS AS ANTAGONISTS OF THE SUBSTANCE P. |
WO1998014193A1 (en) * | 1996-10-04 | 1998-04-09 | Alcon Laboratories, Inc. | The use of a substance p antagonist for the manufacture of a medicament for the treatment of ocular pain |
US5750549A (en) * | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
EP0977572A1 (en) * | 1997-04-24 | 2000-02-09 | Merck Sharp & Dohme Ltd. | Use of nk-1 receptor antagonists for treating eating disorders |
CA2298779A1 (en) * | 1997-08-04 | 1999-02-18 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating aggressive behaviour disorders |
WO1999007376A1 (en) * | 1997-08-04 | 1999-02-18 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating mania |
GB9716463D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
GB9716457D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
GB9816897D0 (en) * | 1998-08-04 | 1998-09-30 | Merck Sharp & Dohme | Therapeutic use |
WO2000010545A2 (en) * | 1998-08-25 | 2000-03-02 | Novartis Ag | Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome |
US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
BR0015320A (en) | 1999-11-03 | 2002-07-09 | Albany Molecular Res Inc | Compound, composition, methods of treating a disorder that is created by, or is dependent on, the decreased availability of serotonin, norepinephrine or dopamine, to inhibit the uptake of synaptic serotonin, dopamine and norepinephrine in a patient in need thereof, and kit |
CN1416346A (en) | 2000-03-21 | 2003-05-07 | 史密丝克莱恩比彻姆公司 | Peotease inhibitors |
US7084152B2 (en) | 2000-07-11 | 2006-08-01 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof |
AU2001292320A1 (en) * | 2000-10-02 | 2002-04-15 | Tanabe Seiyaku Co., Ltd. | Benzylamine compound, process for producing the same, and intermediate therefor |
US6709651B2 (en) | 2001-07-03 | 2004-03-23 | B.M.R.A. Corporation B.V. | Treatment of substance P-related disorders |
EP1460062A4 (en) * | 2001-12-28 | 2005-12-14 | Takeda Pharmaceutical | Nitrogenous cyclic ketone derivative, process for producing the same, and use |
CA2573271C (en) | 2004-07-15 | 2015-10-06 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
CA2584422A1 (en) | 2004-10-18 | 2006-04-27 | Eli Lilly And Company | 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists |
GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
JP5258561B2 (en) | 2005-07-15 | 2013-08-07 | アルバニー モレキュラー リサーチ, インコーポレイテッド | Aryl and heteroaryl substituted tetrahydrobenzazepines and their use to block reuptake of norepinephrine, dopamine and serotonin |
KR20080048502A (en) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
MX2009007200A (en) | 2007-01-10 | 2009-07-15 | Angeletti P Ist Richerche Bio | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors. |
EP2129381A1 (en) | 2007-01-24 | 2009-12-09 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
JP5319518B2 (en) | 2007-04-02 | 2013-10-16 | Msd株式会社 | Indoledione derivative |
AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
JP2011515343A (en) | 2008-03-03 | 2011-05-19 | タイガー ファーマテック | Tyrosine kinase inhibitor |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
AR071997A1 (en) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | CRYSTAL FORM OF 6 - ((4S) -2-METHYL-4- (2-NAFTIL) -1,2,3,4-TETRAHYDROISOQUINOLIN-7-IL) PIRIDAZIN-3-AMINA |
UA105182C2 (en) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
KR20120023072A (en) | 2009-05-12 | 2012-03-12 | 브리스톨-마이어스 스큅 컴퍼니 | Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorohphenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
AU2010247763B2 (en) | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
WO2010132437A1 (en) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
EA023838B1 (en) | 2009-10-14 | 2016-07-29 | Мерк Шарп Энд Домэ Корп. | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP3453762B1 (en) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
JP6280554B2 (en) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
ME02925B (en) | 2012-11-28 | 2018-04-20 | Merck Sharp & Dohme | Compositions and methods for treating cancer |
TW201429969A (en) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | Substituted imidazopyridines as HDM2 inhibitors |
EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE535451A (en) * | 1954-02-05 | |||
GB1060160A (en) * | 1964-08-05 | 1967-03-01 | Allen & Hanburys Ltd | 4-phenylpiperidine derivatives |
US3560510A (en) * | 1969-03-05 | 1971-02-02 | Aldrich Chem Co Inc | 2-benzhydrylquinuclidines |
US3992389A (en) * | 1970-09-03 | 1976-11-16 | John Wyeth & Brother Limited | Heterocyclic compounds |
WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
ES2093099T3 (en) * | 1990-05-31 | 1996-12-16 | Pfizer | PREPARATION OF SUBSTITUTED PIPERIDINES. |
-
1990
- 1990-01-04 WO PCT/US1990/000116 patent/WO1991009844A1/en unknown
- 1990-01-04 UA UA5010406A patent/UA41251C2/en unknown
- 1990-12-14 EP EP90313680A patent/EP0436334B1/en not_active Expired - Lifetime
- 1990-12-14 DK DK90313680.2T patent/DK0436334T3/en active
- 1990-12-14 ES ES90313680T patent/ES2064667T3/en not_active Expired - Lifetime
- 1990-12-14 AT AT90313680T patent/ATE115127T1/en not_active IP Right Cessation
- 1990-12-14 DE DE69014848T patent/DE69014848T2/en not_active Expired - Fee Related
- 1990-12-14 EP EP19930201034 patent/EP0558156A3/en not_active Ceased
- 1990-12-20 NZ NZ236581A patent/NZ236581A/en unknown
- 1990-12-28 IL IL112348A patent/IL112348A/en not_active IP Right Cessation
- 1990-12-28 IL IL96821A patent/IL96821A/en not_active IP Right Cessation
- 1990-12-28 JP JP2409476A patent/JPH0757748B2/en not_active Expired - Fee Related
-
1991
- 1991-01-02 PL PL91293389A patent/PL164244B1/en unknown
- 1991-01-02 CA CA002033497A patent/CA2033497C/en not_active Expired - Fee Related
- 1991-01-02 PL PL91293390A patent/PL164203B1/en not_active IP Right Cessation
- 1991-01-02 PT PT96405A patent/PT96405B/en active IP Right Grant
- 1991-01-02 MY MYPI91000002A patent/MY105438A/en unknown
- 1991-01-02 PL PL91288592A patent/PL163967B1/en not_active IP Right Cessation
- 1991-01-02 HU HU9203403A patent/HU222724B1/en not_active IP Right Cessation
- 1991-01-02 HU HU9203403A patent/HUT68130A/en unknown
- 1991-01-02 PL PL91293392A patent/PL164205B1/en not_active IP Right Cessation
- 1991-01-02 AU AU68621/91A patent/AU625511B2/en not_active Ceased
- 1991-01-02 HU HU9203405A patent/HUT68179A/en unknown
- 1991-01-02 PL PL91293391A patent/PL164204B1/en not_active IP Right Cessation
- 1991-01-02 HU HU916A patent/HUT60719A/en unknown
- 1991-01-02 HU HU9203404A patent/HU220602B1/en unknown
- 1991-01-03 NO NO910016A patent/NO178187C/en unknown
- 1991-01-03 KR KR1019910000001A patent/KR930009441B1/en not_active IP Right Cessation
- 1991-01-03 CN CN91100039A patent/CN1035944C/en not_active Expired - Fee Related
- 1991-01-03 YU YU491A patent/YU48026B/en unknown
- 1991-01-03 ZA ZA9136A patent/ZA9136B/en unknown
- 1991-01-03 FI FI910034A patent/FI114096B/en active
- 1991-01-03 IE IE791A patent/IE63770B1/en not_active IP Right Cessation
- 1991-01-03 BR BR919100016A patent/BR9100016A/en not_active Application Discontinuation
- 1991-01-04 CZ CS199110A patent/CZ289485B6/en not_active IP Right Cessation
- 1991-12-23 RU SU5010406A patent/RU2105758C1/en not_active IP Right Cessation
-
1993
- 1993-08-20 CN CN93116286A patent/CN1045595C/en not_active Expired - Fee Related
-
1995
- 1995-01-16 IL IL11234895A patent/IL112348A0/en unknown
- 1995-02-01 GR GR950400206T patent/GR3014940T3/en unknown
-
2004
- 2004-04-01 FI FI20040479A patent/FI20040479A/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU48026B (en) | 3-AMINOPIPERIDINSKI DERIVATIVES | |
DE68901043D1 (en) | AQUEOUS PHARMACEUTICAL PREPARATION. | |
IT8920929A0 (en) | NEW DERIVATIVES OF R( ) 3 QUINUCLIDINOL. | |
IT8819222A0 (en) | 5 OXY DERIVATIVES OF TETRAHYDROFURAN. | |
FI901277A0 (en) | 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYL PG1Z-DERIVATIVE. | |
FI894812A0 (en) | Process for the preparation of pharmacologically valuable 2-carbonyl-substituted N, N'-di (trimethoxybenzoyl) piperazines | |
DE59010633D1 (en) | 8-Alpha-ACYLAMINO-ERGOLINE, THEIR PRODUCTION AND USE AS A MEDICINAL PRODUCT | |
FI97388B (en) | Process for Preparation of Heterocyclic NMDA Antagonists | |
ES2032573T3 (en) | PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 4,4-DIMETIL-TETRAHIDROPIR-2-ONA. | |
DE69002027D1 (en) | (3-DIETHYLAMINOPROPYL) -1-AMINO-5-METHYLDIPYRIDO (4,3-B) (3,4-F) INDOLTRIHYDROCHLORIDE. | |
IT8867820A0 (en) | PROCEDURE FOR THE PREPARATION OF 1,4-BENZODIAZEPINE-4-ONE DERIVATIVES | |
IT8920570A0 (en) | PROCEDURE FOR THE PREPARATION OF HETEROCYCLIC DERIVATIVES. |